2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

By afschroeder • August 5, 2025

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis. 2025 Aug 4:ciaf424. doi: 10.1093/cid/ciaf424. Epub ahead of print. PMID: 40757658.

Tags: abatacept, covid-19, Harbor UCLA, Infectious Diseases, infliximab, pemivibart, Publications, vilobelimab

Kawasaki Disease in Adults: A Call to Action to Manage Lifelong Coronary Risk

Burns JC, Budoff MJ, Gluckman TJ, Mehran R, Brindis RG, O'Gara PT, Akagi T, Bhatt J, Gordon JB, Newburger JW. Kawasaki Disease in Adults: A[...]

Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study

Fleseriu M, Biller BMK, Webb SM, Strasburger CJ, Georgescu CE, Bidlingmaier M, Wang C, Baciu I, Casanueva FF, Gilis-Januszewska A, Hart G, Manners A, Choe[...]

Non-viable Aspergillus fumigatus promotes chronic inflammation and angiogenesis in a murine fungus ball model

Hamashima R, Tashiro M, Nakano Y, Shirahige T, Namie H, Yano H, Ito Y, Yoshida M, Hirayama T, Takeda K, Iwanaga N, Kakiuchi S, Nishi[...]